Question · asked by 1 review
Pilocarpine vs placebo: Adverse effects (side effects; treatment withdrawals)
- Population
- Patients with radiation-induced salivary gland dysfunction
- Intervention
- Pilocarpine
- Comparison
- placebo
- Outcome
- Adverse effects (side effects; treatment withdrawals)
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Pilocarpine hydrochloride (parasympathomimetic) vs Placebo Adverse effects (side effects; treatment withdrawals) · Patients with radiation-induced salivary gland dysfunction Parasympathomimetic drugs for the treatment of salivary gland dysfunction due to radiotherapy (2015) · Cochrane All outcomes | Johnson 1993 (5 mg tds): sweating 37%, headache 15%, urinary frequency 14%, vasodilatation 12%, dizziness 10%, dyspepsia 10%, nausea 8%, asthenia 8%, diarrhoea 5%; 6% withdrew at 5 mg tds and 29% at 10 mg tds. LeVeque… | 2 studies · 278 participants | GRADE not reported |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Parasympathomimetic drugs for the treatment of salivary gland dysfunction due to radiotherapy 2015 · Cochrane All outcomes | 2015-07 | Not listed | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- Pilocarpine vs Artificial saliva · Patients with radiation-induced salivary gland dysfunction · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.